Loading company…
Orthox develops biomaterial implants to repair knee cartilage and other orthopedic injuries.
Founded in 2008, Orthox develops FibroFix, a silk-derived biomaterial designed to emulate the structure and resilience of human knee cartilage. The company is based in Abingdon, UK, and raised USD 12.5 million in Series A funding in February 2022, led by Parkwalk Advisors with Additio Investment Group participating. The funding was intended to support clinical trials in Bristol and Budapest.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in